AXIM Biotechnologies, Inc. announced that it has successfully developed the world's first rapid, point-of-care, non-invasive diagnostic assay for the detection of abnormal alpha-synuclein, a known biomarker for Parkinson's Disease (PD). A new study released in April of 2023 by the Michael J. Fox Foundation shows that the presence of abnormal alpha-syn nuclein was detected in an astonishing 93% of people with Parkinson's who participated in the study. Furthermore, emerging evidence shows that a-synuclein assays have the potential to differentiate people with PD from healthy controls, enabling the potential for early identification of at-risk groups.

These findings suggest a crucial role for a-synuclein in therapeutic development, both in identifying pathologically defined subgroups of people with Parkinson's disease and establishing biomarker-defined at-risk cohorts. The revolutionary nature of AXIM's new test is that it is non-invasive, inexpensive and it can be performed at a Point-of-Care. It does not require a lumbar puncture, freezing, or sending samples to a lab.

Additionally, studies have shown that total lactoferrin content is reduced in patients with PD. AXIM is already marketing a lactoferrin assay, which may be used in conjunction with the newly developed novel Synuclein test. According to The Parkinson's Foundation, nearly one million people in the U.S. are living with PD.

More than 10 million people worldwide are living with PD. There are currently 219 PD trials going at various Phase I, II and III stages, according to Global Data's Clinical Trial Database supported by a variety of organizations, from institutions to pharmaceutical companies.